| The spike protein of SARS-CoV—a target for vaccine and therapeutic development L Du, Y He, Y Zhou, S Liu, BJ Zheng, S Jiang Nature Reviews Microbiology 7 (3), 226-236, 2009 | 2065 | 2009 |
| Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine W Tai, L He, X Zhang, J Pu, D Voronin, S Jiang, Y Zhou, L Du Cellular & molecular immunology 17 (6), 613-620, 2020 | 1951 | 2020 |
| Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody X Tian, C Li, A Huang, S Xia, S Lu, Z Shi, L Lu, S Jiang, Z Yang, Y Wu, ... Emerging microbes & infections 9 (1), 382-385, 2020 | 1499 | 2020 |
| Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to … S Xia, M Liu, C Wang, W Xu, Q Lan, S Feng, F Qi, L Bao, L Du, S Liu, ... Cell research 30 (4), 343-355, 2020 | 1437 | 2020 |
| Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways Y Ding, LI He, Q Zhang, Z Huang, X Che, J Hou, H Wang, H Shen, L Qiu, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2004 | 1343 | 2004 |
| Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses S Jiang, C Hillyer, L Du Trends in immunology 41 (5), 355-359, 2020 | 1114 | 2020 |
| Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein S Xia, Y Zhu, M Liu, Q Lan, W Xu, Y Wu, T Ying, S Liu, Z Shi, S Jiang, L Lu Cellular & molecular immunology 17 (7), 765-767, 2020 | 829 | 2020 |
| Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications F Wu, A Wang, M Liu, Q Wang, J Chen, S Xia, Y Ling, Y Zhang, J Xun, ... MedRxiv, 2020 | 810 | 2020 |
| Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy H Gu, Q Chen, G Yang, L He, H Fan, YQ Deng, Y Wang, Y Teng, Z Zhao, ... Science 369 (6511), 1603-1607, 2020 | 789 | 2020 |
| HIV-1 inhibition by a peptide. S Jiang, K Lin, N Strick, AR Neurath | 680 | 1993 |
| Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion … S Liu, G Xiao, Y Chen, Y He, J Niu, CR Escalante, H Xiong, J Farmar, ... The Lancet 363 (9413), 938-947, 2004 | 624 | 2004 |
| Recent advances in the detection of respiratory virus infection in humans N Zhang, L Wang, X Deng, R Liang, M Su, C He, L Hu, Y Su, J Ren, F Yu, ... Journal of medical virology 92 (4), 408-417, 2020 | 580 | 2020 |
| Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor L Lu, Q Liu, Y Zhu, KH Chan, L Qin, Y Li, Q Wang, JFW Chan, L Du, F Yu, ... Nature communications 5 (1), 3067, 2014 | 551 | 2014 |
| A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike S Xia, L Yan, W Xu, AS Agrawal, A Algaissi, CTK Tseng, Q Wang, L Du, ... Science advances 5 (4), eaav4580, 2019 | 520 | 2019 |
| Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine Y He, Y Zhou, S Liu, Z Kou, W Li, M Farzan, S Jiang Biochemical and biophysical research communications 324 (2), 773-781, 2004 | 510 | 2004 |
| Subunit vaccines against emerging pathogenic human coronaviruses N Wang, J Shang, S Jiang, L Du Frontiers in microbiology 11, 298, 2020 | 495 | 2020 |
| Expression of elevated levels of pro‐inflammatory cytokines in SARS‐CoV‐infected ACE2+ cells in SARS patients: relation to the acute lung injury and … L He, Y Ding, Q Zhang, X Che, Y He, H Shen, H Wang, Z Li, L Zhao, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2006 | 486 | 2006 |
| Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China F Yu, L Du, DM Ojcius, C Pan, S Jiang Microbes and infection 22 (2), 74-79, 2020 | 472 | 2020 |
| AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells S Wang, Z Qiu, Y Hou, X Deng, W Xu, T Zheng, P Wu, S Xie, W Bian, ... Cell research 31 (2), 126-140, 2021 | 469 | 2021 |
| Quercetin as an antiviral agent inhibits influenza A virus (IAV) entry W Wu, R Li, X Li, J He, S Jiang, S Liu, J Yang Viruses 8 (1), 6, 2015 | 469 | 2015 |
AK DebnathNew York Blood CenterVerified email at nybc.org